Raj Kavin, Mahajan Pranav, Watts Abi, Aedma Surya, Jose Jemin Aby, Jyotheeswara Pillai Keerthana, Rizkalla Adam, Sharma Suyansh, Upadhyay Riddhi, Dhobale Swati, Bin Farooq Talha, Khanam Rukhsaar, Patel Keval V, Martin Randolph
Cardiology, University of California, Riverside, San Bernardino, USA.
Internal Medicine, Carle Foundation Hospital, Urbana, USA.
Cureus. 2022 Nov 30;14(11):e32082. doi: 10.7759/cureus.32082. eCollection 2022 Nov.
Background Coronavirus disease 2019 (COVID-19) infection is associated with troponin elevation, which is associated with increased mortality. However, it is not clear if troponin elevation is independently linked to increased mortality in COVID-19 patients. Although there is considerable literature on risk factors for mortality in COVID-19-associated myocardial injury, the Global Registry of Acute Coronary Events (GRACE), Thrombolysis in Myocardial Infarction (TIMI), and Sequential Organ Failure Assessment (SOFA) scores have not been studied in COVID-19-related myocardial injury. This data is important in risk-stratifying COVID-19 myocardial injury patients. Methodology Of the 1,500 COVID-19 patients admitted to our hospitals, 217 patients who had troponin levels measured were included. Key variables were collected manually, and univariate and multivariate cox regression analysis was done to determine the predictors of mortality in COVID-19-associated myocardial injury. The differences in clinical profiles and outcomes of COVID-19 patients with and without troponin elevation were compared. Results Mortality was 26.5% in the normal troponin group and 54.6% in the elevated troponin group. Patients with elevated troponins had increased frequency of hypotension (p = 0.01), oxygen support (p < 0.01), low absolute lymphocyte (p < 0.01), elevated blood urea nitrogen (p < 0.01), higher C-reactive protein (p < 0.01), higher D-dimer (p < 0.01), higher lactic acid (p < 0.01), and higher Quick SOFA (qSOFA), SOFA, TIMI, and GRACE (all scores p < 0.01). On univariate cox regression, troponin elevation (hazard ratio (HR) = 1.85, 95% confidence interval (CI) = 1.18-2.88, p < 0.01), TIMI score >3 (HRv = 1.79, 95% CI = 1.11-2.75, p = 0.01), and GRACE score >140 (HR = 2.27, 95% CI = 1.45-3.55, p < 0.01) were highly associated with mortality, whereas cardiovascular disease (HR = 1.40, 95% CI = 0.89-2.21, p = 0.129) and cardiovascular risk factors (HR = 1.15, 95% CI = 0.73-1.81, p = 0.52) were not. After adjusting for age, use of a non-rebreather or high-flow nasal cannula, hemoglobin <8.5 g/dL, suspected or confirmed source of infection, and qSOFA and SOFA scores (HR = 1.18, 95% CI = 1.07-1.29, p < 0.01) were independently associated with mortality, whereas troponin (HR = 1.08, 95% CI = 0.63-1.85, p = 0.76), TIMI score (HR = 1.02, 95% CI = 0.99-1.06, p = 0.12) and GRACE scores (HR = 1.01, 95% CI = 0.99-1.02, p = 0.10) were not associated with mortality. Conclusions Our study shows that troponin, GRACE score, and TIMI score are not independent predictors of mortality in COVID-19 myocardial injury. This may be because troponin elevation in COVID-19 patients may be related to demand ischemia rather than acute coronary syndrome-related. This was shown by the association of troponin with a higher degree of systemic inflammation and end-organ dysfunction. Therefore, we recommend SOFA scores in risk-stratifying COVID-19 patients with myocardial injury.
背景 2019 冠状病毒病(COVID-19)感染与肌钙蛋白升高有关,而肌钙蛋白升高与死亡率增加相关。然而,尚不清楚肌钙蛋白升高是否与 COVID-19 患者死亡率增加独立相关。尽管有大量关于 COVID-19 相关心肌损伤死亡率危险因素的文献,但全球急性冠状动脉事件注册研究(GRACE)、心肌梗死溶栓治疗(TIMI)和序贯器官衰竭评估(SOFA)评分在 COVID-19 相关心肌损伤中尚未得到研究。这些数据对于 COVID-19 心肌损伤患者的风险分层很重要。方法 在我院收治的 1500 例 COVID-19 患者中,纳入了 217 例检测了肌钙蛋白水平的患者。通过手动收集关键变量,并进行单因素和多因素 Cox 回归分析,以确定 COVID-19 相关心肌损伤患者死亡率的预测因素。比较了肌钙蛋白升高和未升高的 COVID-19 患者的临床特征和结局差异。结果 肌钙蛋白正常组的死亡率为 26.5%,肌钙蛋白升高组为 54.6%。肌钙蛋白升高的患者低血压发生率增加(p = 0.01)、需要氧支持(p < 0.01)、绝对淋巴细胞计数低(p < 0.01)、血尿素氮升高(p < 0.01)、C 反应蛋白升高(p < 0.01)、D-二聚体升高(p < 0.01)、乳酸升高(p < 0.01)以及 Quick SOFA(qSOFA)、SOFA、TIMI 和 GRACE 评分更高(所有评分 p < 0.01)。在单因素 Cox 回归中,肌钙蛋白升高(风险比(HR)= 1.85,95%置信区间(CI)= 1.18 - 2.88,p < 0.01)、TIMI 评分>3(HRv = 1.79,95%CI = 1.11 - 2.75,p = 0.01)和 GRACE 评分>140(HR = 2.27,95%CI = 1.45 - 3.55,p < 0.01)与死亡率高度相关,而心血管疾病(HR = 1.40,95%CI = 0.89 - 2.21,p = 0.129)和心血管危险因素(HR = 1.15,95%CI = 0.73 - 1.81,p = 0.52)与死亡率无关。在调整年龄、使用非重复呼吸面罩或高流量鼻导管、血红蛋白<8.5 g/dL、疑似或确诊感染源以及 qSOFA 和 SOFA 评分后,(HR = 1.18,95%CI = 1.07 - 1.29,p < 0.01)与死亡率独立相关,而肌钙蛋白(HR = 1.08,95%CI = 0.63 - 1.85,p = 0.76)、TIMI 评分(HR = 1.02,95%CI = 0.99 - 1.06,p = 0.12)和 GRACE 评分(HR = 1.01,95%CI = 0.99 - 1.02,p = 0.10)与死亡率无关。结论 我们的研究表明,肌钙蛋白、GRACE 评分和 TIMI 评分不是 COVID-19 心肌损伤患者死亡率的独立预测因素。这可能是因为 COVID-19 患者的肌钙蛋白升高可能与需求性缺血有关,而非与急性冠状动脉综合征相关。肌钙蛋白与更高程度的全身炎症和终末器官功能障碍相关即表明了这一点。因此,我们建议在对 COVID-19 心肌损伤患者进行风险分层时使用 SOFA 评分。